Creative Planning Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Creative Planning grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,988 shares of the medical equipment provider’s stock after purchasing an additional 1,274 shares during the quarter. Creative Planning’s holdings in Lantheus were worth $2,742,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of LNTH. Silverberg Bernstein Capital Management LLC increased its holdings in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after buying an additional 100 shares during the last quarter. UMB Bank n.a. grew its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC lifted its stake in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. Moody National Bank Trust Division grew its holdings in shares of Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after acquiring an additional 162 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in shares of Lantheus by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock worth $5,353,000 after acquiring an additional 226 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

LNTH stock opened at $110.30 on Friday. The business’s fifty day moving average is $107.32 and its 200-day moving average is $92.93. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a market cap of $7.66 billion, a P/E ratio of 18.08 and a beta of 0.50. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.40 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. Truist Financial decreased their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. B. Riley boosted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Leerink Partners upped their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Finally, Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Insiders Place Their Bets

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,981 shares of company stock worth $2,689,156. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.